Recent

% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

  • stemcellmagnet stemcellmagnet Sep 17, 2013 5:38 PM Flag

    Dermagraft got crushed down 57%

    Majority of top ten products deliver double digit growth
    Q2 2013 Q2 2012 $m$m$m
    Reported Growth
    CER Growth % %
    +13% +13% +22% +25% +46% +46%
    -7% -5% +31% +31% - +1% +15% +15% +56% +56% -57% -57% -9% -8% +10% +11% -16% -16% +7% +8%
    VYVANSE 300
    ELAPRASE 149
    LIALDA / MEZAVANT 138 94 44
    REPLAGAL 114 INTUNIV 90 VPRIV 83 PENTASA

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Growth in total product sales was moderated by DERMAGRAFT® (down 57% to $22 million), ADDERALL XR® (down 16% to $112 million) and REPLAGAL® (down 7% to $114 million; down 5% on a CER basis). Q2 2013 sales for all three products compare against strong prior year comparatives that will ease over the second half of the year.

 
MDXG
9.58+0.27(+2.90%)Sep 2 3:59 PMEDT